Therapy News and Research

RSS

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Pharmacyclics, Inc. today announced data from three Chronic Lymphocytic Leukemia presentations at the American Society of Hematology Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports clinical data from a pooled analysis of 54 patients with CLL or Small Lymphocytic Lymphoma treated with PCI-32765.

6 Dec 2010

Ketogenic diet may benefit patients with myoclonic-astatic epilepsy

Many children with certain forms of epilepsy achieve seizure control through a stringent medically supervised diet, either the ketogenic diet (KD) or a Modified Atkins Diet (MAD). When to use these diets and the mechanisms underlying their anticonvulsant effect are not well defined. Research presented here at the 64th American Epilepsy Society annual meeting provides new insight into when and how these diets work.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Today, Lundbeck Inc. presented positive data from its pivotal phase III study to determine the efficacy and safety profiles of the investigational compound clobazam as adjunctive therapy in treating seizures associated with Lennox-Gastaut syndrome.

6 Dec 2010

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.

6 Dec 2010

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Celgene International Sàrl announced that clinical data from two investigational studies evaluating the use of REVLIMID (lenalidomide) either with rituximab or following a rituximab-containing regimen in patients with chronic lymphocytic leukaemia were presented at the 52nd American Society of Hematology annual meeting.

6 Dec 2010

$Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting$

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

Allos Therapeutics, Inc. today reported new analyses of data from the Company's pivotal PROPEL trial of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma at the 52nd American Society of Hematology Annual Meeting held in Orlando, Florida.

6 Dec 2010

New drug for non-Hodgkin’s lymphoma shows promise

Genentech Inc., now part of Swiss drug developer Roche, and Biogen Idec Inc. on Sunday have announced positive and encouraging results from a clinical study of cancer drug Rituxan in patients with advanced type of non-Hodgkin’s lymphoma. An estimated 65,540 people in the US were diagnosed with non-Hodgkin's lymphoma this year, and follicular lymphoma accounts for about 15 to 20 percent of those cases. The disease can occur at any time during adulthood, though people are typically diagnosed during their 50s and 60s.

5 Dec 2010

Multiple sclerosis therapy breakthrough with stem cells

There seems to a glimmer of hope for tens of thousands of multiple sclerosis sufferers as researchers discover a way to repair damaged nerves with stem cells. The British team says their findings could lead to the development of drugs that repair nerves in the brain and spinal cord and potentially reverse some of the symptoms of MS.

5 Dec 2010

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

US Oncology, Inc., the nation's leading integrated oncology company, announced today that three investigators affiliated with US Oncology Research participated in studies that will be presented orally at the 52nd American Society of Hematology Annual Meeting and Exposition at the Orange County Convention Center in Orlando, Fla. Dec. 4-7. Five other investigators in the US Oncology Research Network participated in a study that will be displayed as a poster during the conference.

4 Dec 2010

Study reveals higher mortality rate among veteran status epilepticus patients

Status epilepticus (SE) is a true medical and neurologic emergency. To better understand the causes, treatment approaches and associated outcomes among SE patients, investigators at the Veterans Affairs Greater Los Angeles Healthcare System retrospectively reviewed all SE cases treated within their system over an eight year period.

4 Dec 2010

ETP, EF announce latest grant recipients of New Therapy Grants Program

The Epilepsy Therapy Project and the Epilepsy Foundation today announced the latest grant recipients of their New Therapy Grants Program, a unique joint venture of two non-profit epilepsy organizations, to advance promising epilepsy research in clinical development.

4 Dec 2010

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet medical needs, primarily for the treatment of neurodegenerative diseases, announced today top-line results from the Company's Phase 1/2 clinical study of NP002 for the treatment of dyskinesias (muscle movement disorders) resulting from levodopa therapy for patients with Parkinson's disease.

4 Dec 2010

Decrease in physician reimbursement leads to decline in AST usage for prostate cancer

The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period.

4 Dec 2010

Sermo releases report on potential replacements for warfarin

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "Potential Replacements for Coumadin (warfarin)." The report gathered feedback from physicians about awareness and understanding of these products and potential barriers to prescribing.

4 Dec 2010

Neurostimulation effective for management of chronic pain

St. Jude Medical, Inc., a global medical device company, today announced two-year results in a post-market clinical study evaluating neurostimulation (spinal cord stimulation) for the management of chronic low back pain. Presented at the 14th annual North American Neuromodulation Society (NANS) meeting in Las Vegas, the study found that 70 percent of neurostimulation patients reported overall pain relief of 50 percent or better at their final two-year visit.

4 Dec 2010

URMC's Cone Beam CT scanner studies presented at RSNA 2010

While questions persist about the best ways to detect breast cancer early, a CT imaging system developed at the University of Rochester Medical Center and first unveiled five years ago is in a better position today to enter the fray -- at least in a supporting role to conventional mammography.

4 Dec 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

The Myelodysplastic Syndromes Foundation today said significant advances are being made in understanding and treating MDS and a related condition, AML (acute myeloid leukemia). Key studies being presented this week include data on new markers and genetic mutations to predict susceptibility to MDS and response to treatment.

4 Dec 2010

Active recreational athletes at risk for shoulder injuries this holiday season, say doctors

Around the holidays, even the friendliest game of flag football can lead to injury. According to sports medicine doctors at Hospital for Special Surgery, older and newly active recreational athletes are particularly at risk for shoulder injuries.

4 Dec 2010

EHSI announces acquisition of Rotary Cell Culture System

Emerging Healthcare Solutions, Inc. announced today that it has acquired a Rotary Cell Culture System, or bioreactor, developed using revolutionary NASA research in the field of microgravity.

4 Dec 2010

Therapy News and Research

Clinical data of PCI-32765 in patients with CLL presented at ASH Annual Meeting

Ketogenic diet may benefit patients with myoclonic-astatic epilepsy

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Lundbeck reports positive phase III study data of clobazam in treating seizures associated with LGS

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Investigational study data of REVLIMID with rituximab or rituximab-containing regimen in CLL patients presented at ASH

Pivotal PROPEL trial data of FOLOTYN in patients with refractory PTCL reported at ASH Annual Meeting

New drug for non-Hodgkin’s lymphoma shows promise

Multiple sclerosis therapy breakthrough with stem cells

Clinical studies participated by three investigators to be presented at ASH Annual Meeting and Exposition

Study reveals higher mortality rate among veteran status epilepticus patients

ETP, EF announce latest grant recipients of New Therapy Grants Program

Positive results from Neuraltus NP002 Phase 1/2 study for levodopa-induced dyskinesias in Parkinson's disease

Decrease in physician reimbursement leads to decline in AST usage for prostate cancer

Sermo releases report on potential replacements for warfarin

Neurostimulation effective for management of chronic pain

URMC's Cone Beam CT scanner studies presented at RSNA 2010

MDS Foundation: Significant advances made in understanding, treating MDS, AML

Active recreational athletes at risk for shoulder injuries this holiday season, say doctors

EHSI announces acquisition of Rotary Cell Culture System

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News